

Konformitätserklärung / Declaration of Conformity


Produktspezifikation / Product details	
Produktebezeichnung / Product name	ActiMaris® Wundgel / ActiMaris® wound gel
Type / Type	20g / 50g
Klassifizierung nach RL 93/42/EWG, Anhang II / Classification according 93/42/EEC, annex II	Klasse IIb, nach Regel 4 / Class IIb, Rule 4

Konformitätsbewertung / Assessment details	
Benannte Stelle / notified body	SIQ, Ljubljana, SI
Verfahren nach RL 93/42 EWG / Route of directive 93/42/EEC	Anhang II, Abschnitt 3 / annex II, section 3
Zertifikate / EC certificates	Reg.no. 43205
NB Bestätigungsschreiben / NB Confirmation letter	7063-2024/1

Firmenspezifische Informationen / Company details	
Bevollmächtigter (EU) / Authorised Representative (EU)	Adriatic Health Factory d.o.o. Nikole Tesle 17 / 44000 Sisak / CROATIA

Angewandte Normen / Used standards	
EN ISO 14971: 2019/A11:2021	Medical devices – Risk management
EN ISO 10993-1:2021	Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management system
EN ISO 15223-1:2021	Symbols for use in the labelling of medical devices

Wir erklären in alleiniger Verantwortung, dass die oben beschriebenen Produkte in der gelieferten Ausführung den Anforderungen der Richtlinie 93/42/EWG und den schweizerischen Medizinproduktegesetzes entsprechen. Die Produkte werden mit dem CE-Kennzeichen versehen.
We declare under sole responsibility that the products described above as delivered are in compliance with directive 93/42/EEC and the medical-device-law of Switzerland. The products are CE marked.



Diese Konformitätserklärung gilt bis / this Declaration of Conformity is valid till: **31.12.2028**

Appenzell, 01.01.2024


ActiMaris AG
Sandgrube 29
9050 Appenzell
Switzerland
www.actimaris.com
Director: Dani Marincic

**Notified Body Confirmation Letter**

2024-01-05

Mr. Dani Marincic
ActiMaris AG
Sandgrube 29
9050 Appenzell
Switzerland

Notified Body Confirmation Letter**Reference: 7063-2024/1**

To whom it may concern,

Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation EU 2023/607 amending Regulations (EU) 2017/745 as regards the transitional provisions for certain medical devices.

This letter confirms that, SIQ Ljubljana, a Notified Body (NB) designated against Regulation (EU) 2017/745 (MDR) and identified by the number 1304 on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer:

Company Name	ActiMaris AG
Legal address/street	Sandgrube 29
Zip code/town	9050 Appenzell
Country:	Switzerland
SRN number	CH-MF-000035551

The devices covered by the formal application and the written agreement mentioned above are identified in the Tables below. Table 1 identifies the devices for which an MDR application has been received, written agreement concluded and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive. Table 2 identifies the devices for which an MDR application has been received and a written agreement concluded, but the NB has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the applicable Directive.

In the case of devices covered by certificates issued under Directive 93/42/EEC (MDD) that expired after 26 May 2021 and before 20 March 2023, without having been withdrawn, this letter also confirms that the manufacturer signed the written agreement under MDR by the date of MDD certificate expiry; or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure

Notified Body Confirmation Letter

in accordance with Article 59(1) of MDR or Article 97(1) of the MDR respectively, by the 20 Mar 2023 for the relevant devices.

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3c of MDR (as amended by (EU) 2023/607), are shown below:

- 26 May 2026 for Class III custom-made implantable devices;
- 31 December 2027 for Class III devices and Class IIb implantable devices excluding Well-established technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors);
- 31 December 2028 for other Class IIb devices, Class IIa, Class I devices placed on the market in sterile condition or have a measuring function;
- 31 December 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments).

On behalf of the Notified Body,

Ana Pribaković Borštnik

Product manager MDR



Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

DEVICE NAME OR BASIC UDI-DI (under MDR Application)	MDR DEVICE CLASSIFICATION (as proposed by the manufacturer and verified at the pre-application stage)	IF THE MDR DEVICE IS A SUBSTITUTE DEVICE, IDENTIFICATION OF THE CORRESPONDING MDD DEVICE	MDD CERTIFICATE REFERENCE(S) OF THE DEVICES UNDER MDR APPLICATION, AND THE NB IDENTIFICATION
ActiMaris Wound Gel 20 g Basic UDI-DI: 764998941100039E	Class III	N/A	Reg.no. 43205, CE 1250
ActiMaris Wound Gel 50 g Basic UDI-DI: 764998941100039E	Class III	N/A	Reg.no. 43205, CE 1250
ActiMaris FORTE Wound Irrigation Solution 300 ml Basic UDI-DI: 764998941100029C	Class III	N/A	Reg.no. 43205, CE 1250
ActiMaris SENSITIVE Wound Irrigation Solution 300 ml Basic UDI-DI: 764998941100019A	Class III	N/A	Reg.no. 43205, CE 1250

**Notified Body Confirmation Letter**

DEVICE NAME OR BASIC UDI-DI (under MDR Application)	MDR DEVICE CLASSIFICATION (as proposed by the manufacturer and verified at the pre-application stage)	IF THE MDR DEVICE IS A SUBSTITUTE DEVICE, IDENTIFICATION OF THE CORRESPONDING MDD DEVICE	MDD CERTIFICATE REFERENCE(S) OF THE DEVICES UNDER MDR APPLICATION, AND THE NB IDENTIFICATION
ActiMaris FORTE Wound Irrigation Solution 1000 ml Basic UDI-DI: 764998941100029C	Class III	N/A	Reg.no. 43205, CE 1250
ActiMaris SENSITIVE Wound Irrigation Solution 1000 ml Basic UDI-DI: 764998941100019A	Class III	N/A	Reg.no. 43205, CE 1250

Table 2: Devices covered by this letter and for which the NB is NOT responsible for appropriate surveillance of the corresponding devices under the applicable Directive

DEVICE NAME OR BASIC UDI-DI (under MDR Application)	MDR DEVICE CLASSIFICATION (as proposed by the manufacturer and verified at the pre-application stage)	IF THE MDR DEVICE IS A SUBSTITUTE DEVICE, IDENTIFICATION OF THE CORRESPONDING MDD DEVICE	MDD CERTIFICATE REFERENCE(S) OF THE DEVICES UNDER MDR APPLICATION, AND THE NB IDENTIFICATION
ActiMaris NASAL Spray 20 ml Basic UDI-DI: 764998941100049G	III	N/A	N/A - Device did not require a Notified Body certificate under Directives
ActiMaris OROPHARYNX Spray 50 ml Basic UDI-DI: 764998941100059J	III	N/A	N/A - Device did not require a Notified Body certificate under Directives
ActiMaris PROCTO Gel 50 g Basic UDI-DI: 764998941100069L	III	N/A	N/A - Device did not require a Notified Body certificate under Directives

Confirmation Letter Revision History

DATE	NB INTERNAL REFERENCE TRACEABLE TO EACH VERSION OF THE LETTER	ACTION
2024/01/05	7063-2024/1	Initial issue